MITSUI-CHEMICALS
5.10.2022 10:01:36 CEST | Business Wire | Press release
Mitsui Chemicals, Inc. (Tokyo: 4183; President & CEO: HASHIMOTO Osamu) and Mitsui Chemicals Europe GmbH (Düsseldorf, Germany; President: HIRAIWA Takeshi) will exhibit at K2022 – the World’s No.1 Trade Fair for Plastics and Rubber as the Mitsui Chemicals Group.
The event is scheduled to be held from October 19–26, 2022 in Düsseldorf, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221005005348/en/
Mitsui Chemicals Group booth (Graphic: Business Wire)
At the trade fair, under the slogan “Feel Good Chemistry for a sustainable world”, the Mitsui Chemicals Group will present innovative materials and solutions that contribute to the circular economy, and a carbon neutral and sustainable society. In addition, technical presentations will be held on October 20th and 24th.
Come and meet us at our booth at K 2022 (hall 7a, booth D18).
- Overview of Mitsui Chemicals Group‘s Exhibition
Exhibition period: |
October 19 (Wed) – October 26 (Wed), 2022 |
Venue: |
Düsseldorf Fairgrounds / Düsseldorf, Germany |
Booth location: |
7a / D18 |
- Exhibition items of Materials and information
Products/Solutions |
Theme |
Arlen™ |
A modified polyamide 6T, heat & hydrolysis resistance for metal replacements and EV components |
Aurum™ |
(TPI), a super engineering plastic for high performance applications at extreme temperatures |
Arcus™ |
Solution service for polymer robot parts including material design/selection and production. |
Exfola™ |
Sealant film for packaging with good oil and water repellency |
Econykol™ |
Biomass based polyols for polyurethanes that contributes to reduce greenhouse gas emissions |
Recycle solutions
|
RePLAYERTM – Renewable plastic layer system - Mono-material packaging solutions Paper packaging solutions |
TAFNEX™ |
Composite material based on polypropylene and carbon fibre for structural and aesthetic applications |
TPXTM |
Polymethylpentene (PMP), a polyolefin based polymer with extremely low density, high melting point, releasability and steam resistance for autoclavable medical and laboratory equipment |
Advanced Module Concept |
Advanced module concept for back-door and slide-door |
Eco-bench |
MMP (Mold Master Plate) - sandwich molding (Recycling) |
- Technical presentations
- October 20, 11:00 o’clock
Theme: "AURUMTM thermoplastic polyimide (TPI)
An innovative solution for the demanding application requirements by maintaining excellent mechanical performance at extreme temperatures"
Presenter: Samer Ziadeh
Technical Expert, Product Support Team, R&D Division
- October 24, 14:00 o’clock
Theme: "Decorative design options with thermoplastic composites based on carbon fiber and polypropylene"
Presenter: Dr. Christos Karatzias
Senior Manager, New Business Development Team, R&D Division
Please visit our dedicated website for more details.
https://eu.mitsuichemicals.com/special/k2022/
About Mitsui Chemicals (Tokyo: 4183, ISIN: JP3888300005)
Mitsui Chemicals’ roots can be traced back to 1912 when it began producing raw material for chemical fertilizers from coal gas byproducts, the first company in Japan to do so. This undertaking significantly contributed to increasing agricultural productivity, a major social issue at the time. Later, the company evolved its technology from coal chemicals to gas chemicals, and in 1958 it built Japan’s first petrochemical complex and so provided impetus to Japan’s industry. Today, the company boasts many world-class products with sales standing at over 1,600 billion yen and with over 160 companies in 30 countries. Its business portfolio includes Life & Healthcare Solutions, Mobility Solutions, ICT Solutions, Basic & Green Materials.
Mitsui Chemicals will continue to contribute to solving social challenges with its state-of-the-art technology and by "Creating New Customer Value through Innovation".
More information can be found at https://www.mitsuichem.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005348/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom